Pascal Soriot, AstraZeneca CEO (Justin Tallis/Press Association via AP Images)
July 29, 2024 07:19 AM EDTUpdated 11:09 AM
R&D

As­traZeneca’s fixed-du­ra­tion Calquence com­bo suc­ceeds in Phase 3 blood can­cer test

Ayisha Sharma

News Reporter

When giv­en with oth­er can­cer drugs for a lim­it­ed time, As­traZeneca’s Calquence hit the pri­ma­ry end­point in a reg­is­tra­tional test, which could open up a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

Am­gen names Stan­ford ge­neti­cist and biotech founder to CSO post

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Cal­tech spin­out de­buts with AI-dri­ven 'mir­ror pep­tide' plat­form

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times